Compare MLP & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLP | ARMP |
|---|---|---|
| Founded | 1909 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.5M | 383.7M |
| IPO Year | 2010 | 1996 |
| Metric | MLP | ARMP |
|---|---|---|
| Price | $16.01 | $11.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 16.0K | ★ 38.3K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,457,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 68.24 | N/A |
| 52 Week Low | $13.84 | $1.11 |
| 52 Week High | $20.34 | $13.75 |
| Indicator | MLP | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 48.16 | 61.86 |
| Support Level | $15.57 | $5.14 |
| Resistance Level | $16.26 | $12.11 |
| Average True Range (ATR) | 0.44 | 1.16 |
| MACD | 0.08 | 0.24 |
| Stochastic Oscillator | 49.13 | 87.14 |
Maui Land & Pineapple Co Inc is a landholding and operating parent company that owns land and commercial property on the island of Maui, Hawaii. The Company puts its assets into productive use by planning, managing, developing, and selling residential, resort, commercial, agricultural, and industrial real estate. Its segments include land development and sales, which cover land planning, entitlement, development, construction, and sales of land assets; leasing, which generates revenue from real property leasing, license fees and royalties, and includes maintenance of real estate assets, conservation activities, and management of water systems in West and Upcountry Maui; and resort amenities, which include a membership program offering benefits within the Kapalua Resort.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.